Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.39 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833115 | 0.85 | AKR1C2 (0.49) | ALBNSD2BCAT1NHERF1 | |
| SCHEMBL6835794 | 0.85 | NHERF1 (0.53) | ALBNHERF1SLC16A1 | |
| SCHEMBL6834154 | 0.83 | KMT2A (0.49) | ALBNHERF1NR1H4 | |
| SCHEMBL6709847 | 0.83 | PLA2G7 (0.47) | PLA2G7NSD2BCAT1 | |
| SCHEMBL6833156 | 0.83 | ALB (0.43) | ALBPLA2G7NHERF1NR1H4 | |
| SCHEMBL6833085 | 0.82 | ALB (0.43) | ALBNSD2NHERF1HTTGFER | |
| SCHEMBL6818302 | 0.82 | NSD2 (0.58) | ALBNSD2NHERF1GFER | |
| SCHEMBL6830559 | 0.82 | NHERF1 (0.45) | ALBNSD2NHERF1HTT | |
| SCHEMBL6712405 | 0.82 | PLA2G7 (0.35) | PLA2G7NSD2BCAT1FEN1 | |
| SCHEMBL6835708 | 0.82 | CCKAR (0.51) | NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885PLA2G7 3381/4885NSD2 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.